LFSC vs. XPH
Compare and contrast key facts about F/m Emerald Life Sciences Innovation ETF (LFSC) and SPDR S&P Pharmaceuticals ETF (XPH).
LFSC and XPH are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024. XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006.
Performance
LFSC vs. XPH - Performance Comparison
Loading graphics...
LFSC vs. XPH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | -4.62% | 56.54% | -6.02% |
XPH SPDR S&P Pharmaceuticals ETF | -2.19% | 31.60% | -6.21% |
Returns By Period
In the year-to-date period, LFSC achieves a -4.62% return, which is significantly lower than XPH's -2.19% return.
LFSC
- 1D
- -0.19%
- 1M
- -3.88%
- YTD
- -4.62%
- 6M
- 18.37%
- 1Y
- 59.47%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
XPH
- 1D
- 1.16%
- 1M
- -4.82%
- YTD
- -2.19%
- 6M
- 13.09%
- 1Y
- 30.74%
- 3Y*
- 11.47%
- 5Y*
- 3.03%
- 10Y*
- 3.94%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
LFSC vs. XPH - Expense Ratio Comparison
LFSC has a 0.54% expense ratio, which is higher than XPH's 0.35% expense ratio.
Return for Risk
LFSC vs. XPH — Risk / Return Rank
LFSC
XPH
LFSC vs. XPH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for F/m Emerald Life Sciences Innovation ETF (LFSC) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LFSC | XPH | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.06 | 1.28 | +0.78 |
Sortino ratioReturn per unit of downside risk | 2.79 | 1.80 | +0.99 |
Omega ratioGain probability vs. loss probability | 1.35 | 1.23 | +0.12 |
Calmar ratioReturn relative to maximum drawdown | 3.42 | 1.97 | +1.45 |
Martin ratioReturn relative to average drawdown | 9.51 | 6.54 | +2.96 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LFSC | XPH | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.06 | 1.28 | +0.78 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.15 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.94 | 0.38 | +0.56 |
Correlation
The correlation between LFSC and XPH is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
LFSC vs. XPH - Dividend Comparison
LFSC has not paid dividends to shareholders, while XPH's dividend yield for the trailing twelve months is around 0.68%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XPH SPDR S&P Pharmaceuticals ETF | 0.68% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Drawdowns
LFSC vs. XPH - Drawdown Comparison
The maximum LFSC drawdown since its inception was -29.74%, smaller than the maximum XPH drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for LFSC and XPH.
Loading graphics...
Drawdown Indicators
| LFSC | XPH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -29.74% | -48.03% | +18.29% |
Max Drawdown (1Y)Largest decline over 1 year | -16.25% | -13.15% | -3.10% |
Max Drawdown (5Y)Largest decline over 5 years | — | -31.63% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -35.97% | — |
Current DrawdownCurrent decline from peak | -11.25% | -6.21% | -5.04% |
Average DrawdownAverage peak-to-trough decline | -8.26% | -17.37% | +9.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.84% | 3.96% | +1.88% |
Volatility
LFSC vs. XPH - Volatility Comparison
F/m Emerald Life Sciences Innovation ETF (LFSC) has a higher volatility of 10.08% compared to SPDR S&P Pharmaceuticals ETF (XPH) at 9.05%. This indicates that LFSC's price experiences larger fluctuations and is considered to be riskier than XPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LFSC | XPH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.08% | 9.05% | +1.03% |
Volatility (6M)Calculated over the trailing 6-month period | 19.95% | 16.40% | +3.55% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.12% | 24.50% | +4.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 29.27% | 20.57% | +8.70% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.27% | 22.22% | +7.05% |